| COMBINED EVALUATION OF C-MET AND HER2 EXPRESSION IN FORMALIN-FIXED AND PARAFFIN-EMBEDDED BLADDER CANCER TISSUES |
| Paper ID : 1050-YRC2022 (R1) |
| Authors |
|
Engy Naguib *1, Taghrid bahig elabasiri2, dahlia badran2, emad ismail2, mahmoud sherief2 1Suez Canal University 2suez canal university |
| Abstract |
| INTRODUCTION Targeted therapy against tyrosine kinase receptors (RTKs) plays an important role in cancer treatment. Understanding the association between RTKs expression and tumor phenotype could better guide clinical drug use. In the present study, the expression status of c-MET and human epidermal growth factor receptor 2 (HER2) in human bladder cancer (BC) and their clinical significance in disease outcome were explored. OBJECTIVES to evaluate c-MET and HER2 genes expression status in bladder cancer patient. METHODS Quantitative real-time polymerase chain reaction was performed in 40 BC patient who had undergone transurethral resection (TUR) or radical cystectomy with pathologically confirmed diagnosis of primary tumor without preoperative chemoradiotherapy and 20 patients with benign diseases as a control. Expression level of c-MET, HER2 and the association with clinicopathological features was analyzed. RESULTS c-MET and HER2 genes expression was significantly elevated up to 6.9 and 4.9 times in study group compared to control group. The frequencies of c-Met and HER2 overexpression in study group were 80% (32/40) and 90% (36/40), respectively. c-MET expression was associated with pathological stage(P=0.002), grade (P=0.019), muscle invasion (P=0.008) and node involvement (P= 0.017), while HER2 expression associated with pathological stage(P=0.033), muscle invasion (P=0.003), node involvement (P=0.005) and multiplicity of tumor (P=0.012). CONCLUSION c-MET and HER2 genes overexpression in BC is associated with poor clinical outcome. |
| Keywords |
| Bladder cancer, Pcr, c-MET, HER2, Gene expression |
| Status: Accepted (Oral Presentation) |
